Sunitinib malate

• Background:

  Sunitinib malate is a receptor tyrosine kinase inhibitor. It has been shown to target VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, c-KIT, FLT3, CSF-1R, Flk-1, and RET.

• Description:

  VEGFR, PDGFR kinase inhibitor

• Product Name Alternative:

  N-[2- (Diethylamino) ethyl]-5-[ (Z) - (5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S) -2-hydroxybutanedioic acid (1:1) salt, SU 011248, SU 11248, SU112248

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cell Signaling | Cancer | Apoptosis | Cardiovascular System | Cancer Growth Inhibitors | Tyrosine Kinase Inhibitors

• Purity:

  ≥99%

• Weight:

  0.025

• Format:

  Yellow solid

• Solubility:

  Soluble in DMSO (40 mg/ml)

• Molecular Formula:

  C22H27FN4O2

• Molecular Weight:

  398.5

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Hersey P., et al. (2009) Annals of Oncology: ESMO. 20 Suppl 6: vi35–40.

• CAS Number:

  557795-19-4